St. Jude Children’s Research Hospital offers a 12-month ASHP-accredited specialized (PGY2) Residency in Clinical Pharmacogenomics.
This program prepares residents to excel in implementing pharmacogenomic testing in clinical practice. The institution’s full integration of an electronic medical record that applies to inpatient and outpatient care, the comprehensive translational research programs, the highly skilled clinical pharmacy specialist team, and the strong laboratory component to the Pharmaceutical Department provides unmatched opportunities for clinical use of pharmacogenetics into patient care.
The resident will learn, contribute and participate in a dynamic environment with world experts translating laboratory-based discoveries into comprehensive medication management for multiple disease states.
St. Jude runs an institution-wide program to implement pre-emptive pharmacogenomic testing (PG4KDS). The resident will assist in directing the PG4KDS program and provide pharmacogenomic consults in the context of a comprehensive approach to pharmaceutical care integrated into the clinical practice areas: general hematology/oncology and bone marrow transplantation. Training will be provided in applied pharmacokinetics, infectious diseases, nutrition support, clinical informatics, and advanced pediatric pharmacotherapy. The resident will work with established clinicians on interdisciplinary teams to deliver personalized pharmacotherapy to pediatric patients with catastrophic diseases.
The resident will design safe and effective patient-centered therapeutic regimens and monitoring plans. In addition, he or she will build pharmacogenomic clinical consults and help develop customized pharmacogenomic clinical decision-support alerts that will alert clinicians of high-risk gene-drug pairs and allow for genetically guided drug dosing. The resident will be expected to write a manuscript for publication and participate in patient education, drug information, quality improvement and medication-outcomes activities.
Residents are highly involved in international efforts to implement pharmacogenomics on a broad scale via participation in the Clinical Pharmacogenetics Implementation Consortium (CPIC). Upon completion of the program, the resident will have the clinical and leadership skills as well as the necessary experience to manage a clinical pharmacogenomics practice, and to implement pharmacogenomic testing in other health-system settings.
Clinical Pharmacogenomics residents learn, contribute and participate in a dynamic environment that consists of professional and technical personnel in both patient care and pharmaceutical research. Along with direct patient care responsibilities, residents will have the opportunity to gain experience in teaching through lectures, in-services, journal club presentations and precepting pharmacy students. A teaching certificate is offered by the University of Tennessee College of Pharmacy. An independent research project will be carried out during the residency, with a presentation of the findings at a national meeting.
Number of Positions
Fist Monday of January by 11:59 p.m. CST
Kristine R. Crews, PharmD, FCCP, BCPS